Abstract
In many African countries, the standardised WHO-recommended combination of tenofovir and lamivudine as nucleotide reverse transcriptase inhibitors (NRTIs), with efavirenz or nevirapine as a non-NRTI (NNRTI), had been preferably used in first-line therapy among adolescents and adults living with HIV.1 However, the high levels of pretreatment drug resistance to NNRTI has prompted WHO to recommend dolutegravir as a component of first-line, second-line, and third-line antiretroviral therapy (ART) regimens.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
